News and Announcements
Board Appointments and Restructure
- Published September 28, 2011 7:13PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Artemis Resources Limited (ASX Code: ARV) announces a restructure of its Board of Directors as follows, with effect from 28 September 2011:
Mr. Guy Robertson, currently the Company’s Chief Operating Officer, is appointed to the Board as Executive Director. Guy has been involved in the mineral exploration business for many years and has acted as Chief Financial Officer and Chief Operating Officer of a number of ASX-listed companies. Guy has a Bachelor of Commerce (Hons.) and is a Chartered Accountant.
—–
To view the full article, please click the link below.
To know more about Artemis Resources Limited, please click here.
Company Updates
Jamie Dimon: Navigating a World of Uncertainty – From Recession Risks to Geopolitical Tensions
In a candid interview with Bloomberg, JPMorgan Chase CEO Jamie Dimon offered a nuanced perspective on the current global economic landscape, a panorama he describes as rife with “a lot of uncertainty.” From lingering recession fears in the US to the complex interplay of trade wars and geopolitical tensions, Dimon, ever the realist, painted a […]
Wholesale Investor and CapitalHQ Sign Exclusive Master Licence with inQ Innovation Global to Provide Access to India’s High-Growth Startup Market
Wholesale Investor and inQ Innovation have forged a strategic partnership, granting global investors direct access to India’s rapidly expanding innovation ecosystem. This exclusive three-year agreement leverages CapitalHQ’s technology to streamline fundraising for Indian startups and expand deal flow for WI’s 45,000-strong investor network, aligning with India’s 2030 Vision for economic growth and innovation.
EBR Systems: Aussie Medtech Ready to Disrupt $3.6B Heart Failure Market with Leadless Pacemaker
Andrew Shute, Senior Vice President of Business Development at EBR Systems, is confident that his Australian medical device company is poised to make a significant impact on the global cardiac rhythm management market. The focus? A novel leadless pacemaker designed to revolutionise treatment for heart failure patients. After years of development and rigorous clinical trials, […]
Backed By Leading Investment Groups and Family Offices
